Skip to main
LENZ
LENZ logo

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics Inc has conducted a comprehensive clinical program through its CLARITY initiative, successfully completing three Phase 3 trials that demonstrated strong efficacy and clean safety, indicating a potentially leading position in the presbyopia treatment market. Furthermore, the company is expected to achieve profitability by 2028, providing a clear timeline for financial growth and stability. Additionally, plans to increase the size of the sales force suggest a proactive approach to capturing market share and enhancing revenue generation following the positive trial outcomes.

Bears say

LENZ Therapeutics faces significant commercial challenges in the presbyopia market, particularly concerning the ability to shift long-standing consumer behavior and the lack of a diversified pipeline beyond its flagship product, Vizz. The company's competitive dynamics are further complicated by the presence of other treatments in development, which, despite being less advanced, raise the competitive bar in the ophthalmic space. Additionally, LENZ may require further funding or strategic partnerships to optimize the value of Vizz, heightening the financial risks associated with its future growth prospects.

LENZ has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 4 analysts, LENZ has a Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.